<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04848662</url>
  </required_header>
  <id_info>
    <org_study_id>AV006</org_study_id>
    <nct_id>NCT04848662</nct_id>
  </id_info>
  <brief_title>This is a Phase 1 Study to Compare Pharmacokinetics of BDA/MDI Compared to Pulmicort Respules in Children With Asthma Aged 4 to 8 Years</brief_title>
  <acronym>BLANC</acronym>
  <official_title>A Phase I, Randomized, Open-label, Single-dose, 2-way Crossover Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 to Pulmicort Respules® in Children With Asthma Aged 4 to 8 Years (BLANC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bond Avillion 2 Development LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bond Avillion 2 Development LP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, single dose, 2-way crossover study to compare the&#xD;
      pharmacokinetics of budesonide delivered by a metered dose inhaler containing budesonide /&#xD;
      albuterol (BDA MDI) compared to budesonide delivered by Pulmicort Respules in children with&#xD;
      asthma aged 4 to 8 Years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Actual">July 8, 2021</completion_date>
  <primary_completion_date type="Actual">July 5, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>0 to 720 minutes after dose</time_frame>
    <description>area under the plasma concentration-time curve from time zero to time of last quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0 to 720 minutes after dose</time_frame>
    <description>Maximum observed plasma concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>0 to 720 minutes after dose</time_frame>
    <description>time to reach maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tlast</measure>
    <time_frame>0 to 720 minutes after dose</time_frame>
    <description>Time of last quantifiable plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½λz</measure>
    <time_frame>0 to 720 minutes after dose</time_frame>
    <description>Half-life associated with terminal slope (λz) of a semi-logarithmic concentration time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz</measure>
    <time_frame>0 to 720 minutes after dose</time_frame>
    <description>Terminal elimination rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clast</measure>
    <time_frame>0 to 720 minutes after dose</time_frame>
    <description>Drug concentration at last observed (quantifiable) concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf (if feasible)</measure>
    <time_frame>0 to 720 minutes after dose</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to infinity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of AEs/SAEs</measure>
    <time_frame>4 weeks</time_frame>
    <description>To assess the safety and tolerability of BDA MDI and Pulmicort Respules</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>BDA MDI (PT027) 160/180 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmicort Respules 1 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDA MDI (PT027) 160/180 μg</intervention_name>
    <description>Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/90 μg per puff. Two puffs to administer 160/180 μg dose.</description>
    <arm_group_label>BDA MDI (PT027) 160/180 μg</arm_group_label>
    <other_name>PT027</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pulmicort Respules 0.5 MG/ML Inhalation Suspension</intervention_name>
    <description>Budesonide 0.5 mg/ml. Each 2 ml Respule contains 1 mg budesonide.</description>
    <arm_group_label>Pulmicort Respules 1 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of informed consent prior to any study specific procedures. Children should&#xD;
             provide assent to join the study, as applicable. The child's parent(s) or legally&#xD;
             authorized representative (LAR) must sign the informed consent form (ICF). The LAR&#xD;
             must be aged ≥18 years old.&#xD;
&#xD;
          2. Male or female aged between 4 and 8 years inclusive (not having reached his/her 9th&#xD;
             birthday by the time of screening.&#xD;
&#xD;
          3. Weigh at least 14 kg or higher.&#xD;
&#xD;
          4. Clinician diagnosed asthma of at least 3 months.&#xD;
&#xD;
          5. Stable on treatment with albuterol PRN and/or ICS and/or leukotriene receptor&#xD;
             antagonists (LTRAs) for 2 weeks prior to screening; children taking budesonide in any&#xD;
             form at Visit 1 will be switched to another corticosteroid with a washout of&#xD;
             budesonide of 3 to 7 days.&#xD;
&#xD;
          6. Demonstrate ability to correctly use the nebulizer and metered-dose inhaler (MDI)&#xD;
             device without a spacer.&#xD;
&#xD;
          7. Willingness and ability of the child and parent(s)/LAR to comply with the demands of&#xD;
             the study as described in the informed consent/assent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to change from any budesonide therapy to another suitable corticosteroid.&#xD;
&#xD;
          2. History of life-threatening asthma defined as any asthma episode associated with loss&#xD;
             of consciousness, intubation or admission to an intensive care unit.&#xD;
&#xD;
          3. Unstable asthma as judged by the Investigator (eg, any change in asthma therapy within&#xD;
             2 weeks prior to screening or use of more than 2 occasions of rescue medication&#xD;
             (albuterol) per day within 1 week prior to screening (potential for rescreen).&#xD;
&#xD;
          4. Children receiving regular maintenance treatment with prohibited anti-inflammatory or&#xD;
             long-acting bronchodilator asthma medication (inhaled, nebulized, oral, or systemic)&#xD;
             within 1 month prior to screening.&#xD;
&#xD;
          5. More than 1 short course of oral/rectal/systemic corticosteroids within 6 months&#xD;
             preceding screening (Visit 1), or any oral/rectal/systemic corticosteroids within 30&#xD;
             days prior to screening.&#xD;
&#xD;
          6. Evidence of active concomitant pulmonary disease other than asthma (children with&#xD;
             stable allergic rhinitis will be permitted, as long as, there are no changes in the&#xD;
             treatment and the medications do not interfere with the analytical assay methods).&#xD;
&#xD;
          7. Upper respiratory infection involving antibiotic treatment not resolved within 14 days&#xD;
             prior to Visit 1.&#xD;
&#xD;
          8. Children with a known or suspected hypersensitivity to albuterol/salbutamol,&#xD;
             budesonide or any of the excipients used in the IMPs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IPS Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TTS Research</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <zip>78006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plans to share IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

